Status:
COMPLETED
Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion
Lead Sponsor:
Melbourne Health
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion. Atrial fibrillation is a heart cond...
Eligibility Criteria
Inclusion
- Patients with persistent Atrial Fibrillation on Warfarin.
Exclusion
- paroxysmal atrial fibrillation with self terminating episodes.
- left atrial size\>6.0cm
- myocardial infarction in the previous 6 months.
- contraindications to amiodarone use .
- cardiac surgery in the previous 3 months .
- an acute reversible illness contributing to the development of af
- a QTc interval \> 480ms.
- pregnancy
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00232219
Start Date
January 1 2003
End Date
November 1 2013
Last Update
May 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Melbourne hospital
Melbourne, Victoria, Australia, 3050